<DOC>
	<DOCNO>NCT02130973</DOCNO>
	<brief_summary>This three-year study evaluate effect sequential therapy Forteo ( teriparatide ) denosumab bone density spine , hip , leg forearm .</brief_summary>
	<brief_title>The Treatment Osteoporosis Using Combination Teriparatide ( Forteo ) Denosumab</brief_title>
	<detailed_description>In order maximize early anabolic effect teriparatide ( TPTD ) , avoid development tachyphylaxis continue daily administration TPTD beyond 6 month , cyclic therapy might optimal . Since Denosumab ( Prolia ) potent antiresorptive agent rapid off-effect , might optimal agent help maximize bone gain cyclic TPTD/antiresorptive therapy . Our primary hypothesis increment bone density spine DXA great woman randomize receive cyclic sequential regimen ( three separate 6 month cycle daily subcutaneous TPTD , follow one subcutaneous injection Denosumab ) compare daily sequential therapy ( 18 month daily subcutaneous TPTD follow Denosumab therapy 18 month ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Subjects postmenopausal &gt; age 45 , racial origin . They must osteoporosis medication . They willing participate duration study physical psychological illness would prohibit participate . Pregnant woman , protect individual ( institutionalize ) , unable give inform consent recruit . Exclusion criterion detail . Subjects meet initial prescreening criterion present site screen visit full medical history , brief physical exam , BMD lab evaluation confirm eligibility . Osteoporosis define DXA BMD TScore &lt; 2.5 lumbar spine ( least 2 evaluable vertebra L1 L4 ) , total hip femoral neck . In addition , woman confirm vertebral deformity radiograph lateral DXA image , prior osteoporosisrelated fracture age &gt; 45 along DXA BMD TScore &lt; 1.5 one skeletal sit eligible participate . The use drug know affect skeletal calcium homeostasis . Multiple vertebral fracture severe lumbar degenerative change fewer 2 evaluable lumbar vertebra Current use antiresorptive medicine Use Hormone/Estrogen Therapy , raloxifene calcitonin within past 3 month Use oral bisphosphonate 4 month within past 2 year 5 year total cumulative bisphosphonate use past 10 year Use intravenous ibandronate within past 18 month Use intravenous zoledronic acid within past 4 year A history symptomatic renal stone within past 3 year history multiple symptomatic renal stone Skeletal Disorders osteoporosis include : Hypercalcemia , hyperparathyroidism , Paget 's Disease osteomalacia Untreated uncontrolled thyroid disease Elevated Bone Specific Alkaline Phosphatase level History external internal radiation therapy Renal insufficiency estimate GFR 30 ml/min Liver function test ( ALT/AST ) 1.5 time upper limit normal Clinically significant hyperuricemia active gout Any contraindication receipt Teriparatide Denosumab ( include hypocalcemia ) History atypical fracture femoral shaft</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>teriparatide</keyword>
	<keyword>Forteo</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Prolia</keyword>
	<keyword>bone density</keyword>
	<keyword>treatment</keyword>
</DOC>